Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

January 7, 2020

Study Completion Date

January 7, 2020

Conditions
Malaria,Falciparum
Interventions
DRUG

Pyronaridine Tetraphosphate/Artesunate

Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.

DRUG

Dihydroartemisinin/Piperaquine

Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.

DRUG

Primaquine Diphosphate

Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.

Trial Locations (2)

Unknown

Malaria Research and Training Centre, Bamako

Radboud university medical center, Nijmegen

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

Radboud University Medical Center

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission | Biotech Hunter | Biotech Hunter